Company Dossier · Health Care
Bio-Techne
- S&P 500
- Russell 1000
What Bio-Techne is doing, read from its filings, its own words and the news, with every figure dated and sourced. Not investment advice: no ratings, no price targets.
Open the full company record in Palanor: guidance, KPIs, ownership, calls, prices →
The latest read
Computed from the data on Oct 22, 2026. Every figure links back to its source in the sections below.
- Revenue over the four quarters to June 30, 2026: $1.22 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Free cash flow (operating cash flow minus capital expenditure) over the four quarters to June 30, 2026: $0.26 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Capital expenditure over the four quarters to June 30, 2026: $0.03 billion, about level with a year earlier.SEC EDGAR filings (XBRL)
- Share buybacks in the fiscal year to June 30, 2026: $0.04 billion.SEC EDGAR filings (10-K)
- Latest earnings call or results release (August 12, 2026): sentiment 0.10 on a −1 to +1 scale (mixed), confidence 0.20 of 1.Palanor Discourse
- Latest annual report (filed August 24, 2026): 4 risk factors added, 0 removed.Risk Factor Changes (10-K Item 1A)
- Insiders were net sellers in Q2 2026: $0.3 million on the open market.SEC Form 4
- 599 institutional managers reported a position at June 30, 2026 (+14 on the quarter before).SEC Form 13F
- H-1B filings certified in Q2 2026: 6 (13 a year earlier).U.S. Department of Labor (OFLC)
Company Posture
How Company Posture is measured →What Bio-Techne is doing, on three axes, from its filings and its own words, as of 2026-10-22. A description, not a rating: Company Posture never says whether to buy.
Steady · Hedging
Expanding ↔ Retrenching
Steady
- Capital spending42nd pct
- Debt raised—
- Buybacks vs capex71st pct
- Hiring filings70th pct
- Deals and private raises49th pct
- Patent publications25th pct
Confident ↔ Hedging
Hedging
- Call sentiment28th pct
- Call confidence2nd pct
- Guidance changes—
- Risk factors added6th pct
- Insider open-market trades44th pct
Pressure
Components only: Not yet shown as a score: in the back-test it did not add to a naive reader's forecast of impairment, debt acceleration or bankruptcy filings (8-K 2.06, 2.04, 1.03) (not enough events (17 in half 1; needs 20)).
- Fails-to-deliver80th pct
- Stress filings48th pct
Credit
How these are built →Bio-Techne's borrowing from its SEC filings: the bonds it priced and the debt on its latest balance sheet. A description, not a rating.
Debt on the balance sheet
$0.2B
- Due within a year $0.0B
- Longer term $0.2B
- Default point $0.1B (short + ½ long)
Finance leases included · Jun 30, 2026 filing
Bonds priced, last 12 months
None
U.S. dollar tranches with a term sheet on EDGAR. Deals sold under Rule 144A file none and are not counted.
Charts
Live charts: each one redraws from today’s data and has an image link to paste into a document or slide.
Cash flow
Capital returned and raised
What the company says
Hiring and ownership
Filings and records
The last two years of notable 8-Ks, offerings, annual reports, federal awards, lobbying reports, patents and other public records, newest first.
- Oct 16, 2026LobbyingLobbying report (SQUIRE PATTON BOGGS)third_quarter 2026
- Sep 23, 20268-KShareholder vote resultsItem 5.07
- Aug 24, 202610-KAnnual report (10-K)4 risk factors added, 0 removed
- Aug 11, 2026Patent
- Jul 16, 2026LobbyingLobbying report (SQUIRE PATTON BOGGS)second_quarter 2026
- Jun 26, 20268-KMaterial agreement signedItem 1.01
- Jun 26, 20268-KDirector or officer changeItem 5.02
- May 12, 2026Patent
- Apr 15, 2026LobbyingLobbying report (SQUIRE PATTON BOGGS)first_quarter 2026
- Mar 17, 2026Patent
- Mar 10, 2026Patent
- Feb 11, 20268-KDirector or officer changeItem 5.02
- Feb 3, 2026Patent
- Jan 14, 2026LobbyingLobbying report (SQUIRE PATTON BOGGS)fourth_quarter 2025
- Nov 12, 2025Trademark
- Nov 12, 2025Trademark
- Nov 12, 2025Trademark
- Nov 12, 2025Trademark
- Nov 5, 20258-KShareholder vote resultsItem 5.07
- Oct 14, 2025LobbyingLobbying report (SQUIRE PATTON BOGGS)third_quarter 2025
- Aug 22, 202510-KAnnual report (10-K)0 risk factors added, 0 removed
- Aug 12, 2025Trademark
- Jul 15, 2025LobbyingLobbying report (SQUIRE PATTON BOGGS)second_quarter 2025
- Apr 14, 2025LobbyingLobbying report (SQUIRE PATTON BOGGS)first_quarter 2025
- Mar 4, 20258-KDirector or officer changeItem 5.02
- Feb 5, 20258-KDirector or officer changeItem 5.02
- Jan 13, 2025LobbyingLobbying report (SQUIRE PATTON BOGGS)fourth_quarter 2024
- Nov 5, 20248-KDirector or officer changeItem 5.02
- Oct 30, 20248-KShareholder vote resultsItem 5.07
- Aug 22, 202410-KAnnual report (10-K)0 risk factors added, 0 removed
Peers
Companies in the same industry in the S&P 500, Russell 1000 or MidCap 400, closest in revenue first. Trailing twelve months, from SEC filings.
| Company | Revenue | Free cash flow | Through |
|---|---|---|---|
| Bio-Rad Laboratories BIO | $2.6B | $0.3B | Jun 30, 2026 |
| Charles River Laboratories CRL | $4.0B | $0.4B | Jun 27, 2026 |
| Mettler Toledo MTD | $4.1B | $0.9B | Jun 30, 2026 |
| Illumina, Inc. ILMN | $4.5B | $0.9B | Jun 28, 2026 |
| Waters Corporation WAT | $4.6B | — | Jul 4, 2026 |
| Agilent Technologies A | $7.4B | $1.3B | Jul 31, 2026 |
| IQVIA IQV | $16.6B | $2.1B | Mar 31, 2026 |
| Sotera Health SHC | $1.2B | $0.1B | Jun 30, 2026 |